A putative therapeutic target in glioblastoma multiforme: P60484

Ablatotech Signals reports today on a putative therapeutic target — P60484 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in glioblastoma multiforme.

Background

The putative target P60484, also known as "Eukaryotic translation initiation factor 4 gamma 1" (EIF4G1), has garnered attention as a candidate in the study of glioblastoma multiforme (GBM). As one of the most aggressive and prevalent forms of brain cancer, GBM presents significant therapeutic challenges, underscoring the need for novel targets such as P60484. Preliminary expression profiling suggests that P60484 may play a role in GBM biology, indicating its potential as a therapeutic target that warrants further investigation.

Data-mining rationale

The rationale for investigating P60484 arises from a systematic data-mining effort that cross-referenced reviewed human entries in UniProt associated with glioblastoma multiforme against 722 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Notably, P60484 was identified in several expression-profiling studies; however, it currently lacks a registered Phase 1 or higher clinical program. This gap suggests a potential oversight in the exploration of this candidate's role in GBM.

Why prior analyses may have missed this

Many of the GEO datasets that included P60484 were generated prior to the implementation of modern empirical-Bayes statistical methods, such as the limma package, which allows for more accurate multiple-testing corrections. Consequently, earlier analyses may not have sufficiently captured the expression dynamics of P60484 in GBM. The lack of rigorous statistical validation may have contributed to an underestimation of its potential significance in the disease context.

Reasoning for further validation

To substantiate the potential role of P60484 in glioblastoma multiforme, several experimental approaches are suggested: 1. **Re-analyze matched GEO datasets**: Utilize the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to identify differentially expressed genes, including P60484. 2. **Validate top differentially-expressed genes**: Perform quantitative PCR (qPCR) in an independent cohort of GBM samples to confirm the expression levels of P60484 and other top candidates. 3. **Check tissue specificity**: Leverage resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess the tissue-specific expression patterns of P60484. 4. **Run pathway context analyses**: Utilize tools like STRING and OmniPath to explore the potential pathways and interactions involving P60484, providing insights into its biological role in GBM. 5. **Assess druggability**: If validation of P60484's expression and function is achieved, evaluate its druggability using databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.

References

UniProt. P60484 - Eukaryotic translation initiation factor 4 gamma 1. [Link](https://www.uniprot.org/uniprot/P60484)
NCBI GEO. GDS:200320501, GDS:200318047, GDS:200318046, GDS:200318045, GDS:200300771. [Link](https://www.ncbi.nlm.nih.gov/geo/)
Ritchie ME, et al. (2015). "Limma powers differential expression analyses for RNA-sequencing and microarray studies." *Nucleic Acids Research*, 43(7): e47. DOI: 10.1093/nar/gkv007
GTEx Portal. [Link](https://gtexportal.org/)
Human Protein Atlas. [Link](https://www.proteinatlas.org/)

References